Healthcare provider profile · identity verified

Katie Maureen Goodwin, MD

Internal Medicine · PORTLAND, OR · NPI 1740465970

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	497	146
Amlodipine Besylate	Amlodipine Besylate	199	64
Losartan Potassium	Losartan Potassium	199	55
Levothyroxine Sodium	Levothyroxine Sodium	138	36
Lisinopril	Lisinopril	123	40
Trazodone Hcl	Trazodone Hcl	102	35
Gabapentin	Gabapentin	99	28
Alendronate Sodium	Alendronate Sodium	95	29
Tamsulosin Hcl	Tamsulosin Hcl	84	23
Albuterol Sulfate Hfa	Albuterol Sulfate	73	33
Metformin Hcl	Metformin Hcl	72	21
Biktarvy	Bictegrav/Emtricit/Tenofov Ala	71	25
Metformin Hcl Er	Metformin Hcl	71	26
Finasteride	Finasteride	67	19
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	66	suppressed
Simvastatin	Simvastatin	65	20
Potassium Chloride	Potassium Chloride	59	16
Metoprolol Tartrate	Metoprolol Tartrate	55	20
Alvesco	Ciclesonide	54	24
Valacyclovir	Valacyclovir Hcl	52	14
Allopurinol	Allopurinol	47	suppressed
Glipizide	Glipizide	47	19
Hydrochlorothiazide	Hydrochlorothiazide	47	17
Atenolol	Atenolol	46	12
Duloxetine Hcl	Duloxetine Hcl	46	13
Meloxicam	Meloxicam	46	17
Metoprolol Succinate	Metoprolol Succinate	43	12
Pantoprazole Sodium	Pantoprazole Sodium	42	16
Bupropion Xl	Bupropion Hcl	41	13
Clopidogrel	Clopidogrel Bisulfate	41	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	40	13
Fluoxetine Hcl	Fluoxetine Hcl	39	11
Ondansetron Odt	Ondansetron	39	suppressed
Sertraline Hcl	Sertraline Hcl	36	suppressed
Carvedilol	Carvedilol	35	suppressed
Furosemide	Furosemide	33	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	33	13
Tivicay	Dolutegravir Sodium	33	11
Pravastatin Sodium	Pravastatin Sodium	32	13
Acyclovir	Acyclovir	31	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	27	suppressed
Juluca	Dolutegravir/Rilpivirine	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	26	16
Warfarin Sodium	Warfarin Sodium	25	suppressed
Fluticasone Propionate	Fluticasone Propionate	23	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	22	20
Estradiol	Estradiol	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Ketoconazole	Ketoconazole	20	suppressed
Omeprazole	Omeprazole	20	suppressed
Abacavir	Abacavir Sulfate	19	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	19	suppressed
Ozempic	Semaglutide	19	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Abacavir-Lamivudine	Abacavir Sulfate/Lamivudine	17	suppressed
Odefsey	Emtricitab/Rilpiviri/Tenof Ala	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	17	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Humulin N	Insulin Nph Human Isophane	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Vemlidy	Tenofovir Alafenamide	15	suppressed
Emtricitabine-Tenofovir Disop	Emtricitabine/Tenofovir (Tdf)	14	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Naproxen	Naproxen	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Azithromycin	Azithromycin	11	suppressed
Citalopram Hbr	Citalopram Hydrobromide	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Famotidine	Famotidine	11	suppressed
Ritonavir	Ritonavir	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error